MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
4.990
-0.280
-5.31%
After Hours: 5.00 +0.01 +0.20% 19:30 10/02 EDT
OPEN
5.37
PREV CLOSE
5.27
HIGH
5.66
LOW
4.880
VOLUME
147.70K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
3.350
MARKET CAP
109.21M
P/E (TTM)
-1.5562
1D
5D
1M
3M
1Y
5Y
1D
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
Barchart · 23h ago
AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline
Barchart · 2d ago
Weekly Report: what happened at AARD last week (0921-0925)?
Weekly Report · 4d ago
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 09/25 16:15
Aardvark Therapeutics Price Target Maintained With a $6.00/Share by RBC Capital
Dow Jones · 09/24 13:37
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
Benzinga · 09/24 13:27
Aardvark Therapeutics, Inc. (AARD) Gets a Hold from RBC Capital
TipRanks · 09/24 10:45
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
Barchart · 09/21 11:21
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.